Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Increase in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 180,400 shares, an increase of 205.8% from the January 31st total of 59,000 shares. Based on an average daily trading volume, of 367,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 4.5% of the company’s shares are sold short.

Virax Biolabs Group Trading Down 2.3 %

Shares of NASDAQ VRAX opened at $1.67 on Friday. Virax Biolabs Group has a fifty-two week low of $0.60 and a fifty-two week high of $9.00. The business’s 50 day moving average price is $2.00 and its 200-day moving average price is $2.29.

Institutional Trading of Virax Biolabs Group

A hedge fund recently bought a new stake in Virax Biolabs Group stock. XTX Topco Ltd purchased a new position in Virax Biolabs Group Limited (NASDAQ:VRAX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned about 0.37% of Virax Biolabs Group at the end of the most recent quarter. 8.61% of the stock is owned by institutional investors.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.